Studies with cyclic adenosine monophosphate receptor and stimulation of in vitro transcription of the Gal operon.
D000818:Animals; D001426:Bacterial Proteins / Q000378:metabolism*; D001666:Binding Sites, Antibody; D003090:Coliphages; D000242:Cyclic AMP / Q000378:metabolism* / Q000494:pharmacology; D006152:Cyclic GMP / Q000494:pharmacology; D004267:DNA Viruses; D004279:DNA, Viral / Q000378:metabolism; D012321:DNA-Directed RNA Polymerases / Q000378:metabolism*; D004355:Drug Stability; D004926:Escherichia coli / Q000201:enzymology / Q000378:metabolism*; D005690:Galactose; D007106:Immune Sera; D008274:Magnesium / Q000494:pharmacology; D009876:Operon; D011485:Protein Binding; D012333:RNA, Messenger / Q000096:biosynthesis; D011817:Rabbits / Q000276:immunology; D011955:Receptors, Drug; D012265:Ribonucleotides / Q000494:pharmacology; D012293:Rifampin / Q000494:pharmacology; D014158:Transcription, Genetic / Q000187:drug effects*
D001426:Bacterial Proteins; D004279:DNA, Viral; D007106:Immune Sera; D012333:RNA, Messenger; D011955:Receptors, Drug; D012265:Ribonucleotides; D000242:Cyclic AMP; D012321:DNA-Directed RNA Polymerases; D006152:Cyclic GMP; D008274:Magnesium; D012293:Rifampin; D005690:Galactose